secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016657
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio doses first patient with nula-cel for sickle cell disease; proof-of-concept data mid-2023
--------------------------------------------------------------------------------

- First patient dosed with nula-cel (formerly GPH101) in Phase 1/2 CEDAR trial for sickle cell disease.
- Nula-cel is a gene editing therapy designed to directly correct the SCD mutation and restore healthy hemoglobin.
- Initial proof-of-concept data from the CEDAR trial expected in mid-2023.
- FDA granted Fast Track and Orphan Drug designations for nula-cel.
- Phase 1/2 trial to enroll ~15 patients with severe SCD at multiple U.S. sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017022016657/0000950170-22-016657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017022016657/grph-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer